Neil Woodford Pumps Cash Into GlaxoSmithKline plc, Purplebricks Group PLC & CityFibre Infrastructure Holdings PLC

Top fund manager Neil Woodford is backing GlaxoSmithKline plc (LON:GSK), Purplebricks Group PLC (LON:PURP) and CityFibre Infrastructure Holdings PLC (LON:CFHL).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Should you sell everything and run for the hills when markets are in turmoil? Of course not! Some of your best long-term returns will come from buying when bearish sentiment pervades.

Still, selectivity may be wise when global economic growth is being downgraded. With this in mind, I’ve been looking at the latest buys reported by ace fund manager Neil Woodford’s equity income fund.

GlaxoSmithKline (LSE: GSK), Purplebricks (LSE: PURP) and CityFibre (LSE: CFHL) are three stocks Woodford has been funnelling cash into.

GlaxoSmithKline

Big pharmaceuticals companies have long been core holdings in Woodford’s funds. It is an industry he sees as “fundamentally undervalued”.

The performance of FTSE 100 giant GlaxoSmithKline has been “frustratingly disappointing” for some years, but Woodford maintains that the market is under-appreciating the group’s HIV and consumer healthcare businesses, and that the sum of the parts is significantly greater than the whole.

As such, the fund has further increased its stake in Glaxo “at attractive valuation levels”. The company is expected to return to growth this year, and trades on 16 times forecast earnings with a running yield of 5.9%. I can see why Woodford has been keen to snap up more shares in this defensive blue-chip heavyweight.

Purplebricks

Companies with exposure to the UK housing market have seen a strong recovery since the financial crisis. However, you won’t find the likes of housebuilders Barratt, Persimmon and Taylor Wimpey, or property portals Rightmove and Zoopla in Woodford’s portfolio. His favoured play on the sector is “hybrid estate agency” Purplebricks.

Woodford had been a major backer of Purplebricks when it was a private company, and upped his stake when it joined the stock market in December. His buying just before Christmas gave him ownership of 29.1% of the company’s shares.

The attraction of the company to Woodford? “Purplebricks already sells more properties than all the main online agents combined and its IPO is the latest step as it seeks to cement its leading position in the UK”.

The placing price of the shares was 100p, but the January market turmoil has seen a fall to 73p, so you can buy today at a good discount to the price Woodford was willing to pay. This fast-growing company is expected to turn a profit for the first time in 2017, and currently trades on 22 times that year’s forecast earnings.

CityFibre Infrastructure

CityFibre is a designer, builder, owner, and operator of fibre optic infrastructure in UK towns and cities. Last month the company raised £80m in a placing to facilitate the £90m acquisition of certain national infrastructure assets of KCOM Group.

Woodford participated in the fundraising at 50p a share, attracted by an acquisition that expands CityFibre’s footprint to 36 cities and major towns, and which “accelerates the company’s growth plans”. Woodford sits just behind another renowned investor — Odey Asset Management — at the head of the shareholder register with an 11.3% stake in the company.

With heavy capital expenditure, CityFibre isn’t expected to make a bottom-line profit for some years. But if Woodford and Odey are right this small-cap company will grow to be worth considerably more than its current £155m valuation at 58.5p.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Sunrise over Earth
Investing Articles

Meet the ex-penny share up 109% that has topped Rolls-Royce and Nvidia in 2025

The share price of this investment trust has gone from pennies to above £1 over the past couple of years.…

Read more »

House models and one with REIT - standing for real estate investment trust - written on it.
Investing Articles

1 of the FTSE 100’s most reliable dividend stocks for me to buy now?

With most dividend stocks with 6.5% yields, there's a problem with the underlying business. But LondonMetric Property is a rare…

Read more »

Investing Articles

Is 2026 the year to consider buying oil stocks?

The time to buy cyclical stocks is when they're out of fashion with investors. And that looks to be the…

Read more »

ISA coins
Investing Articles

3 reasons I’m skipping a Cash ISA in 2026

Putting money into a Cash ISA can feel safe. But in 2026 and beyond, that comfort could come at a…

Read more »

US Stock

I asked ChatGPT if the Tesla share price could outperform Nvidia in 2026, with this result!

Jon Smith considers the performance of the Tesla share price against Nvidia stock and compares his view for next year…

Read more »

Investing Articles

Greggs: is this FTSE 250 stock about to crash again in 2026?

After this FTSE 250 stock crashed in 2025, our writer wonders if it will do the same in 2026. Or…

Read more »

Investing Articles

7%+ yields! Here are 3 major UK dividend share forecasts for 2026 and beyond

Mark Hartley checks forecasts and considers the long-term passive income potential of three of the UK's most popular dividend shares.

Read more »

Hand is turning a dice and changes the direction of an arrow symbolizing that the value of an ETF (Exchange Traded Fund) is going up (or vice versa)
Investing Articles

2 top ETFs to consider for an ISA in 2026

Here are two very different ETFs -- one set to ride the global robotics boom, the other offering a juicy…

Read more »